Assembly Biosciences
ASMB
37 hedge funds and large institutions have $10.1M invested in Assembly Biosciences in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.49% less ownership
Funds ownership: 2.42% → 1.93% (-0.49%)
5% less funds holding
Funds holding: 39 → 37 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
44% less capital invested
Capital invested by funds: $18M → $10.1M (-$7.91M)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$369K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$114K |
| 3 |
Two Sigma Investments
New York
|
+$53.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$45.3K |
| 5 |
Morgan Stanley
New York
|
+$18.3K |
Top Sellers
ASMB Hedge Fund Activity: Q1 2023 in Review
37 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q1 2023, worth a combined $10.1M — down 44% from $18M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ASMB and 3 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $369K. The largest seller was Deep Track Capital, exiting entirely with an estimated $2.38M sold.
- 37 institutional investors held Assembly Biosciences (ASMB) as of Q1 2023, down from 39 in Q4 2022.
- Funds reported $10.1M of Assembly Biosciences stock for Q1 2023, down 44% quarter-over-quarter.
- 3 funds opened new Assembly Biosciences positions in Q1 2023 and 5 closed out, a net change of -2 holders.
- The largest Assembly Biosciences buyer in Q1 2023 was Renaissance Technologies, an estimated $369K added.
- The largest Assembly Biosciences seller in Q1 2023 was Deep Track Capital, an estimated $2.38M sold.
Based on aggregated 13F filings for Q1 2023.